Which antibiotic used for periodontal disease is delivered as a sustained-release form?

Arestin is correctly identified as an antibiotic used for periodontal disease that is delivered in a sustained-release form. It contains minocycline, which is an antibiotic effective in combatting the bacteria associated with periodontal infections. Arestin is formulated as a microsphere that is placed directly into the periodontal pockets during a dental procedure. Once in place, the microspheres dissolve over time, allowing the antibiotic to be released gradually. This sustained-release characteristic helps maintain therapeutic drug levels at the site, improving treatment outcomes in managing periodontal disease.

Other options provided, while related to periodontal treatment, either utilize different mechanisms or are not recognized primarily for sustained-release delivery of antibiotics. For example, Atridox is an antibiotic gel formulation that is injected into the periodontal pocket but is not specifically designed for prolonged release like Arestin. Actisite is a fiber that delivers tetracycline but is used in a different form than the sustained-release mechanism of Arestin. Periochip is a chlorhexidine chip that provides an antimicrobial effect but operates without the same sustained-release technology specific to Arestin. Understanding the unique delivery systems and their implications in periodontal therapy is crucial for effective treatment planning.